Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRN-002 (crofelemer) for the symptomatic treatment of diarrhea-predominant irritable bowel syndrome (d-IBS) in females

Next Previous
X
Search
Trial Profile

A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRN-002 (crofelemer) for the symptomatic treatment of diarrhea-predominant irritable bowel syndrome (d-IBS) in females

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crofelemer (Primary)
  • Indications Irritable bowel syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bausch Health Companies; Trine Pharmaceuticals

    • Most Recent Events

    • 24 Dec 2008 Results have been published in Digestion - International Journal of Gastroenterology, according to a Napo Pharmaceuticals media release.
    • 01 Jan 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
    • 29 Jun 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top